At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Tirzepatide (drug), Placebo (drug)
- How long the study runs
- Study runs about 78 months (dates as stated)
- About the drug or intervention
- Tirzepatide — drug: Administered SC · Placebo — drug: Administered SC
- Patient visit burden
- "The study will last approximately 76 weeks and may include up to 23 visits." (as stated by sponsor)
- Type of study
- Testing a treatment
- Ages
- 12 Years to 17 Years
- Who
- All
- Number of participants
- 300
- Started
- 2024-06-03
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for obesity
- • Phase3 - 300 participants
- • The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities
Who can take part?
- • Ages 12 Years to 17 Years
- • Diagnosed with obesity
Where?
- • Cambridge - Addenbrooke's Hospital
- • Glagow - Royal Hospital for Children
- • Leeds - Leeds General Infirmary
- • Leicester - Leicester Royal Infirmary
- • +5 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
More detail
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity with multiple weight related comorbidities.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 12 Years - 17 Years
- Who can join: All genders
What the study is looking for
- ✓Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
- ✓Are capable of giving signed agreement to take part by a legal representative or assent by a study participant (when...
Who cannot take part
- ✗Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to
- ✗gastric bypass
- ✗sleeve gastrectomy
- ✗restrictive bariatric surgery, such as Lap-Band gastric banding, or
- ✗any other procedure intended to result in weight reduction.
See the full criteria
Where Is This Study? (9 UK sites)
Addenbrooke's Hospital
Cambridge CB2 0SL, United Kingdom
Royal Hospital for Children
Glagow G51 4TF, United Kingdom
Leeds General Infirmary
Leeds LS1 3EX, United Kingdom
Leicester Royal Infirmary
Leicester LE1 5WW, United Kingdom
Carolyn Maloney
uhl-tr.researchandinnovationadminmailbox@nhs.net0116 258 8351Alder Hey Children's Hospital
Liverpool L14 5AB, United Kingdom
Paediatric and Adolescent OutpatientsElizabeth Garrett Anderson WingUniversity College Hospital
London WC1E 6DB, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne NE1 4PL, United Kingdom
Sheffield Children's Hospital
Sheffield S10 2TH, United Kingdom
Southampton General Hospital
Southampton SO16 6YD, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT
